Anne De Paepe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anne De Paepe has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Lieve Nuytinck
Innogenetics NV, Ghent, Belgium
5 shared publications - Bart Loeys
University of Antwerp
3 shared publications - Geert Mortier
University of Antwerp
2 shared publications - Kathleen Bertha Michaël Claes
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
2 shared publications L. Messiaen
Centre for Medical Genetics, Ghent University Hospital, Belgium
2 shared publications- Ludwine Messiaen
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
2 shared publications
Latest Publications
- 1 September 2011
- Vol. 74 (3) , 421-6
The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP).
FAP is characterized by 100-1000s of adenomatous polyps in colon and rectum, and is in 70% of the patients associated with extracolonic manifestations. Attenuated FAP (AFAP) is a less severe form of FAP, marked by the presence of < 100 polyps and a later onset of colorectal cancer (CRC). (A)FAP is caused by autosomal dominantly inherited mutations in the APC (Adenomatous polyposis coli) gene, a tumour suppressor gene that controls beta-catenin turnover in the Wnt pathway. De novo occurrence is reported in 30-40% of the patients. Mutations are detected in 85% of classical FAP families, while only 20%-30% of AFAP cases will exhibit a germline APC mutation. MUTYH is the second (A)FAP-related gene and is involved with base-excision repair of DNA damaged by oxidative stress. MUTYH mutations are inherited in an autosomal recessive way and account for 10%-20% of classical FAP cases without an APC mutation and for 30% of AFAP cases. Genotype-phenotype correlations exist for mutations in the APC gene, however, contradictions in the literature caution against the sole use of the genotype for decisions regarding clinical management. Once the family's specific APC mutation is identified in the proband, predictive testing for first degree relatives is possible from the age of 10 to 12 years on. For AFAP, relatives are tested at age 18 and older. Opinions about the appropriate ages at which to initiate genetic testing may vary. Physicians must have a discussion about prenatal testing with patients in childbearing age. They may either opt for conventional prenatal diagnosis (amniocentesis or chorionic villous sampling) or for preimplantation genetic diagnosis (PGD).
- 1 September 2011
- Vol. 74 (3) , 421-6
The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP).
FAP is characterized by 100-1000s of adenomatous polyps in colon and rectum, and is in 70% of the patients associated with extracolonic manifestations. Attenuated FAP (AFAP) is a less severe form of FAP, marked by the presence of < 100 polyps and a later onset of colorectal cancer (CRC). (A)FAP is caused by autosomal dominantly inherited mutations in the APC (Adenomatous polyposis coli) gene, a tumour suppressor gene that controls beta-catenin turnover in the Wnt pathway. De novo occurrence is reported in 30-40% of the patients. Mutations are detected in 85% of classical FAP families, while only 20%-30% of AFAP cases will exhibit a germline APC mutation. MUTYH is the second (A)FAP-related gene and is involved with base-excision repair of DNA damaged by oxidative stress. MUTYH mutations are inherited in an autosomal recessive way and account for 10%-20% of classical FAP cases without an APC mutation and for 30% of AFAP cases. Genotype-phenotype correlations exist for mutations in the APC gene, however, contradictions in the literature caution against the sole use of the genotype for decisions regarding clinical management. Once the family's specific APC mutation is identified in the proband, predictive testing for first degree relatives is possible from the age of 10 to 12 years on. For AFAP, relatives are tested at age 18 and older. Opinions about the appropriate ages at which to initiate genetic testing may vary. Physicians must have a discussion about prenatal testing with patients in childbearing age. They may either opt for conventional prenatal diagnosis (amniocentesis or chorionic villous sampling) or for preimplantation genetic diagnosis (PGD).
- Open Access
- 1 September 2002
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 11 (18) , 2113-2118
Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa
Hereditary cutis laxa comprises a heterogeneous group of connective tissue disorders characterized by loose skin and variable systemic involvement. Autosomal dominant and recessive as well as X-linked forms have been described. Some dominant forms are caused by mutations in the elastine gene (ELN). The X-linked form is now classified in the group of copper transport diseases. The genetic defect underlying the autosomal recessive (AR) forms of cutis laxa is not known. The phenotypic abnormalities recently observed in a fibulin-5 knockout mouse model are reminiscent of human AR cutis laxa type I. Both share cutis laxa, lung emphysema and arterial involvement. Molecular study of the fibulin-5 (FBLN5) gene in a large consanguineous Turkish family with four patients affected by AR cutis laxa type I demonstrated the presence of a homozygous missense mutation (T998C) in the FBLN5 gene resulting in a serine-to-proline (S227P) substitution in the fourth calcium-binding epidermal growth factor-like domain of fibulin-5 protein. This amino acid substitution is predicted to have important structural and functional consequences for normal elastogenesis. As such, we provide evidence that a genetic defect in fibulin-5 (FBLN5, also known as EVEC or DANCE) is responsible for a recessive form of cutis laxa in humans.
- 1 September 2002
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 11 (18) , 2113-2118
Open AccessHomozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa
Hereditary cutis laxa comprises a heterogeneous group of connective tissue disorders characterized by loose skin and variable systemic involvement. Autosomal dominant and recessive as well as X-linked forms have been described. Some dominant forms are caused by mutations in the elastine gene (ELN). The X-linked form is now classified in the group of copper transport diseases. The genetic defect underlying the autosomal recessive (AR) forms of cutis laxa is not known. The phenotypic abnormalities recently observed in a fibulin-5 knockout mouse model are reminiscent of human AR cutis laxa type I. Both share cutis laxa, lung emphysema and arterial involvement. Molecular study of the fibulin-5 (FBLN5) gene in a large consanguineous Turkish family with four patients affected by AR cutis laxa type I demonstrated the presence of a homozygous missense mutation (T998C) in the FBLN5 gene resulting in a serine-to-proline (S227P) substitution in the fourth calcium-binding epidermal growth factor-like domain of fibulin-5 protein. This amino acid substitution is predicted to have important structural and functional consequences for normal elastogenesis. As such, we provide evidence that a genetic defect in fibulin-5 (FBLN5, also known as EVEC or DANCE) is responsible for a recessive form of cutis laxa in humans.
- Open Access
- 24 May 2002
- Published by Springer Nature in BMC Genomics
- Vol. 3 (1) , 13
Complex splicing pattern generates great diversity in human NF1 transcripts
Mutation analysis of the neurofibromatosis type 1 (NF1) gene has shown that about 30% of NF1 patients carry a splice mutation resulting in the production of one or several shortened transcripts. Some of these transcripts were also found in fresh lymphocytes of healthy individuals, albeit typically at a very low level. Starting from this initial observation, we were interested to gain further insight into the complex nature of NF1 mRNA processing. We have used a RT-PCR plasmid library based method to identify novel NF1 splice variants. Several transcripts were observed with specific insertions/deletions and a survey was made. This large group of variants detected in one single gene allows to perform a comparative analysis of the factors involved in splice regulation. Exons that are prone to skipping were systematically analysed for 5' and 3' splice site strength, branch point strength and secondary structure. Our study revealed a complex splicing pattern, generating a great diversity in NF1 transcripts. We found that, on average, exons that are spliced out in part of the mRNA have significantly weaker acceptor sites. Some variants identified in this study could have distinct roles and might expand our knowledge of neurofibromin.
- 24 May 2002
- Published by Springer Nature in BMC Genomics
- Vol. 3 (1) , 13
Open AccessComplex splicing pattern generates great diversity in human NF1 transcripts
Mutation analysis of the neurofibromatosis type 1 (NF1) gene has shown that about 30% of NF1 patients carry a splice mutation resulting in the production of one or several shortened transcripts. Some of these transcripts were also found in fresh lymphocytes of healthy individuals, albeit typically at a very low level. Starting from this initial observation, we were interested to gain further insight into the complex nature of NF1 mRNA processing. We have used a RT-PCR plasmid library based method to identify novel NF1 splice variants. Several transcripts were observed with specific insertions/deletions and a survey was made. This large group of variants detected in one single gene allows to perform a comparative analysis of the factors involved in splice regulation. Exons that are prone to skipping were systematically analysed for 5' and 3' splice site strength, branch point strength and secondary structure. Our study revealed a complex splicing pattern, generating a great diversity in NF1 transcripts. We found that, on average, exons that are spliced out in part of the mRNA have significantly weaker acceptor sites. Some variants identified in this study could have distinct roles and might expand our knowledge of neurofibromin.
- 24 January 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (1) , 22-28
Strategies for prenatal and preimplantation genetic diagnosis in Marfan syndrome (MFS)
- 24 January 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (1) , 22-28
Strategies for prenatal and preimplantation genetic diagnosis in Marfan syndrome (MFS)
- 1 February 2001
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 56 (1) , 10-16
HERITABLE COLLAGEN DISORDERS: FROM GENOTYPE TO PHENOTYPE
- 1 February 2001
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 56 (1) , 10-16
HERITABLE COLLAGEN DISORDERS: FROM GENOTYPE TO PHENOTYPE
- 1 June 2000
- Published by Springer Nature in Human Genetics
- Vol. 106 (6) , 605-613
Two pregnancies after preimplantation genetic diagnosis for osteogenesis imperfecta type I and type IV
- 1 June 2000
- Published by Springer Nature in Human Genetics
- Vol. 106 (6) , 605-613
Two pregnancies after preimplantation genetic diagnosis for osteogenesis imperfecta type I and type IV
- 1 April 2000
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 66 (4) , 1398-1402
Classical Ehlers-Danlos Syndrome Caused by a Mutation in Type I Collagen
- 1 April 2000
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 66 (4) , 1398-1402
Classical Ehlers-Danlos Syndrome Caused by a Mutation in Type I Collagen
- 1 January 2000
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 55 (5) , 244-248
Presymptomatic testing for genetic diseases: new frontiers, new dilemmas.
- 1 January 2000
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 55 (5) , 244-248
Presymptomatic testing for genetic diseases: new frontiers, new dilemmas.
- 1 July 1999
- Published by Wolters Kluwer Health in Clinical Dysmorphology
- Vol. 8 (3) , 179???184-184
Occipital Horn syndrome in a 2-year-old boy
The clinical presentation of Occipital Horn syndrome, a rare X-linked recessive condition, in a 2-year-old boy is described. This is the youngest patient reported so far. The major clinical, pathophysiological and molecular aspects of this condition are summarized. Occipital Horn syndrome
- 1 July 1999
- Published by Wolters Kluwer Health in Clinical Dysmorphology
- Vol. 8 (3) , 179???184-184
Occipital Horn syndrome in a 2-year-old boy
The clinical presentation of Occipital Horn syndrome, a rare X-linked recessive condition, in a 2-year-old boy is described. This is the youngest patient reported so far. The major clinical, pathophysiological and molecular aspects of this condition are summarized. Occipital Horn syndrome
- Open Access
- 1 January 1999
- Published by Wiley in Disease Markers
- Vol. 15 (1-3) , 191-195
Genetic Counselling and Testing for Hereditary Breast and Ovarian Cancer: The Gent(le) Approach
The counselling experience with 50 Flemish families in whom mutation analysis of the total coding region of the BRCA1 and BRCA2 gene has been initiated, is presented.Genetic testing for breast‐ovarian cancer susceptibility is offered by a multidisciplinary team. During the counselling sessions, special attention is given to comprehensible and emotionally acceptable communi‐cation of genetic information and to the psychosocial evaluation of the counselee. The limitations of molecular testing and the controversy surrounding cancer prevention strategies are also discussed.The overall acceptance of mutation testing is high. Some of the problems encountered are inaccuracy of the reported family history, poor retrieval of the medical records of affected family members and the reluctance of many patients to inform their relatives about the possibility of being tested.
- 1 January 1999
- Published by Wiley in Disease Markers
- Vol. 15 (1-3) , 191-195
Open AccessGenetic Counselling and Testing for Hereditary Breast and Ovarian Cancer: The Gent(le) Approach
The counselling experience with 50 Flemish families in whom mutation analysis of the total coding region of the BRCA1 and BRCA2 gene has been initiated, is presented.Genetic testing for breast‐ovarian cancer susceptibility is offered by a multidisciplinary team. During the counselling sessions, special attention is given to comprehensible and emotionally acceptable communi‐cation of genetic information and to the psychosocial evaluation of the counselee. The limitations of molecular testing and the controversy surrounding cancer prevention strategies are also discussed.The overall acceptance of mutation testing is high. Some of the problems encountered are inaccuracy of the reported family history, poor retrieval of the medical records of affected family members and the reluctance of many patients to inform their relatives about the possibility of being tested.